Does Rallies show 13F holders for VOR?

Yes. Rallies tracks hedge fund and 13F ownership data for VOR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is VOR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VOR. It does not provide personalized investment advice.

VOR (Vor Biopharma Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Vor Biopharma Inc. Common Stock (VOR) is a publicly traded Healthcare sector company. As of May 21, 2026, VOR trades at $15.35 with a market cap of $765.65M and a P/E ratio of -0.21. VOR moved +10.12% today. Year to date, VOR is +46.98%; over the trailing twelve months it is +335.57%. Its 52-week range spans $2.62 to $65.80. Analyst consensus is strong buy with an average price target of $33.80. Rallies surfaces VOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns VOR stock?

Hedge funds tracked by Rallies that own VOR include Renaissance Technologies, Citadel Advisors, Two Sigma, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Vor Biopharma Inc. Common Stock.

VOR Key Metrics

Key financial metrics for VOR
Metric	Value
Price	$15.35
Market Cap	$765.65M
P/E Ratio	-0.21
EPS	$-70.50
Dividend Yield	0.00%
52-Week High	$65.80
52-Week Low	$2.62
Volume	850
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-695.98M
Gross Margin	0.00%

Top Hedge Funds Holding VOR

Renaissance Technologies holds 529.50K shares of VOR, changed -29.96% as of Dec 31, 2024.
Citadel Advisors holds 200.41K shares of VOR, changed +28007.29% as of Dec 31, 2024.
Two Sigma holds 163.06K shares of VOR, changed +18.91% as of Dec 31, 2024.
Two Sigma holds 27.50K shares of VOR, changed -45.33% as of Dec 31, 2024.

Latest VOR News

Vor Bio Secures $491.5M Runway, Advances Phase 3 Telitacicept Trials with H1 2027 Data — May 13, 2026
Vor Bio Secures $75M, Doses First Sjögren’s Patient, Raises Cash to $530M — Mar 30, 2026

Recent VOR Insider Trades

RA CAPITAL MANAGEMENT, L.P. sold 165.15K (~$2.60M) on Apr 22, 2026.
RA CAPITAL MANAGEMENT, L.P. sold 171.96K (~$2.71M) on Apr 20, 2026.
RA CAPITAL MANAGEMENT, L.P. sold 458.41K (~$7.46M) on Apr 17, 2026.

VOR Analyst Consensus

6 analysts cover VOR: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.80.

Common questions about VOR

Who owns VOR stock?: Hedge funds tracked by Rallies that own VOR include Renaissance Technologies, Citadel Advisors, Two Sigma, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Vor Biopharma Inc. Common Stock.
Does Rallies show 13F holders for VOR?: Yes. Rallies tracks hedge fund and 13F ownership data for VOR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is VOR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VOR. It does not provide personalized investment advice.